23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
03. März 2025 16:35 ET
|
23andMe, Inc.
SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a...
23andMe Launches New Genetic Report on Osteoporosis
31. Januar 2025 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human...
23andMe Special Committee Announces Exploration of Strategic Alternatives
28. Januar 2025 17:25 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
28. Januar 2025 17:15 ET
|
23andMe, Inc.
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- 23andMe...
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
08. Januar 2025 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
20. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a...
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
12. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
11. November 2024 17:30 ET
|
23andMe, Inc.
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all...
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
07. November 2024 17:54 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the...
23andMe to Report Q2 FY2025 Financial Results
07. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial...